Methods of prediction and prevention of pre-eclampsia: Systematic reviews of accuracy and effectiveness literature with economic modelling

Health Technology Assessment

Volumn 12, Issue 6, 2008, Pages 1-249

  Meads, C A ^a   Cnossen, J S ^b   Meher, S ^c   Juarez Garcia, A ^a   Ter Riet, G ^b,d   Duley, L ^e   Roberts, T E ^a   Mol, B W ^b   Van der Post, J A ^b   Leeflang, M M ^b   Barton, P M ^a   Hyde, C J ^a   Gupta, J K ^f   Khan, K S ^f  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF LIVERPOOL   (United Kingdom)

^d UNIVERSITY OF ZURICH   (Switzerland)

^e BRADFORD INSTITUTE FOR HEALTH RESEARCH   (United Kingdom)

^f BIRMINGHAM WOMEN S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA FETOPROTEIN; ALPHA TOCOPHEROL; ANTIHYPERTENSIVE AGENT; ANTIOXIDANT; ANTITHROMBOCYTIC AGENT; ASCORBIC ACID; BETA CAROTENE; CALCIUM; CATALASE; DIURETIC AGENT; FISH OIL; GARLIC EXTRACT; GLUTATHIONE PEROXIDASE; IODINE; IRON; MAGNESIUM; MANGANESE; MINERAL; MULTIVITAMIN; NITRIC OXIDE DONOR; PLACEBO; PROGESTERONE; RETINOL; SELENIUM; SUPEROXIDE DISMUTASE; UNINDEXED DRUG; URIC ACID; VITAMIN B GROUP; VITAMIN D;

BED REST; BLOOD ANALYSIS; BLOOD PRESSURE MONITORING; BODY MASS; CLINICAL TRIAL; COCHRANE LIBRARY; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; DOPPLER FLOWMETRY; DRUG COST; ECONOMIC ASPECT; EXERCISE; HEALTH CARE COST; HUMAN; HYPERTENSION; INCIDENCE; LIFESTYLE MODIFICATION; LOW DRUG DOSE; NATIONAL HEALTH SERVICE; NUTRITIONAL SUPPORT; PANCREATITIS; PATHOPHYSIOLOGY; PERINATAL DEATH; PHYSICAL ACTIVITY; POLYACRYLAMIDE GEL ELECTROPHORESIS; PREDICTION; PREECLAMPSIA; PREMATURITY; PROGNOSIS; PROTEINURIA; REVIEW; RISK REDUCTION; SENSITIVITY AND SPECIFICITY; SIDE EFFECT; SMALL FOR DATE INFANT; SYSTEMATIC REVIEW; URIC ACID BLOOD LEVEL; UTERINE ARTERY; COST BENEFIT ANALYSIS; DIAGNOSTIC TEST; ECONOMICS; FEMALE; METHODOLOGY; PREGNANCY; PRIMARY PREVENTION; STATISTICAL MODEL;

COST-BENEFIT ANALYSIS; DIAGNOSTIC TESTS, ROUTINE; FEMALE; HUMANS; MODELS, ECONOMETRIC; PRE-ECLAMPSIA; PREGNANCY; PRIMARY PREVENTION;

EID: 44349145923     PISSN: 13665278     EISSN: None     Source Type: Journal    
DOI: 10.3310/hta12060     Document Type: Review

References (201)

1. Gifford RW Jr, August PA, Cunningham G, Green LA, Lindhemier MD, McNellis D, et al. Report of the national high blood pressure education program working group on high blood pressure in pregnancy. Am J Obst Gynecol 2000;183 Suppl:1-22.
2. World Health Organization International Collaborative Study of Hypertensive Disorders in Pregnancy. Geographic variation in the incidence of hypertension in pregnancy. Am J Obstet Gynecol 1988;158:80-3.
3. Brown MA, Hague WM, Higgins J, Lowe S, McCowan L, Oats J. The detection, investigation, and management of hypertension in pregnancy: full consensus statement. Aust N Z J Obstet Gynaecol 2000; 40:139-55.
4. Brown MA, Lindheimer MD, deSweit M, Van Assche A, Moutquin J. The classification and diagnosis of the hypertensive disorders of pregnancy: statement from the international society for the study of hypertension in pregnancy (ISSHP). Hypertens Pregnancy 2001;20:9-14.
5. Redman CWG, Jefferies M. Revised definition of pre-eclampsia. Lancet 1988;331(8589):809-12.
6. Helewa ME, Burrows RF, Smith J, Williams K, Brain P, Rabkin SW. Report of the Canadian Hypertension Society Consensus Conference: 1. Definitions, evaluation and classification of hypertensive disorders in pregnancy. CMAJ 1997;157:715-25.
7. Quinn M. Automated blood pressure measurement devices: potential source of morbidity in preeclampsia? Am J Obst Gynecol 1994;170(5 Pt 1): 1303-7.
8. Rubin, P. Measuring diastolic blood pressure in pregnancy. BMJ 1996;313:4-5.
9. Engelhard IM, van Rij M, Boullart I, Ekhart THA, Spaanderman M, van den Hout MA, et al. Posttraumatic stress disorder after pre-eclampsia: an exploratory study. Gen Hosp Psychiat 2002;24:260-4.
10. Mignini LE, Villar J, Khan KS. Mapping the theories of preeclampsia: the need for systematic reviews of mechanisms of the disease. Am J Obstet Gynecol 2006;194:317-21.
11. Scott JS. Pregnancy toxaemia associated with hydrops foetalis, hydatidiform mole and hydramnios. J Obstet Gynaecol Br Emp 1958; 65: 689-701.
12. Piering WF, Garancis JG, Becker CG, Beres JA, Lemann J Jr. Pre-eclampsia related to a functioning extrauterine placenta: report of a case and 25 year follow-up. Am J Kidney Dis 1993;21: 310-13.
13. Khong TY, De Wolf F, Robertson WB, Brosens I. Inadequate maternal vascular response to placentation in pregnancies complicated by preeclampsia and small for date gestational age infants. BJOG 1986;93:1049-59.
14. Brosens IA, Robertson WB, Dixon HG. The role of spiral arteries in the pathogenesis of preeclampsia. Obstet Gynecol Ann 1972; 1:177-91.
15. Roberts JM, Lain KY. Recent insights into the pathogenesis of pre-eclampsia. Placenta 2002;23: 359-72.
16. Hubel CA, Kagan VE, Kisin ER, McLanghlin MK, Roberts JM. Increased ascorbate radical formation and ascorbate depletion in plasma from women with preeclampsia: implications for oxidative stress. Free Rad Biol Med 1997;23:597-609.
17. Hubel CA, Roberts JM, Taylor RN, Musci TJ, Rogers GM, McLaughlin MK. Lipid peroxidation in pregnancy: new perspectives on pre-eclampsia. Am J Obstet Gynecol 1989;161:1025-34.
18. Conrad KP, Benyo DF. Placental cytokines and the pathogenesis of preeclampsia. Am J Reprod Immunol 1997;37:240-9.
19. Cockell AP, Learmont JG, Smarason AK, Redman CWG, Sargent ILP. Human placental syncitiotrophoblast microvillour membranes impair maternal vascular endothelial function. BJOG 1997;104:235-40.
20. Roberts JM. Pregnancy related hypertension. In Creasy RK, Resnick R, editors. Maternal fetal medicine. Philadelphia, PA: WB Saunders; 1998.
21. Strickland DM, Guzick DS, Cox Kea. The relationship between abortion in the first pregnancy and development of pregnancy induced hypertension in the subsequent pregnancy. Am J Obstet Gynecol 1986; 154:146-8.
22. Caritis S, Sibai B, Hauth J, Lindheimer M, Ban Dorsten P, Klebanoff M. Predictors of preeclampsia in women at high risk. Am J Obstet Gynecol 1998;179:946-51.
23. Conde-Agudelo A, Belizan JM. Risk factors for pre-eclampsia in a large cohort of Latin American and Caribbean women. BJOG 2000; 107:75-83.
24. Ness RB, Roberts JM. Epidemiology of hypertension. In Lindheimer M, Roberts JM, Cunningham G, editors. Chesley's hypertensive disorders of pregnancy. Stamford, CT: Appleton and Lange; 1999.
25. Rey E, Couturier A. The prognosis of pregnancy in women with chronic hypertension. Am J Obstet Gynecol 1994;171:410-16.
26. Cunningham FG, Cox SM, Harstad TW, Mason RA, Pritchard JA. Chronic renal disease and pregnancy outcome. Am J Obstet Gynecol 1990; 163:453-9.
27. Dekker GA, de Vries JIP, Doelitzsch PM, Huijgens PC, von Blomberg BME, Jakobs C, et al. Underlying disorders associated with severe early-onset preeclampsia. Am J Obstet Gynaecol 1995; 173: 1042-8.
28. Long PA, Oats JN. Pre-eclampsia in twin pregnancy: severity and pathogenesis. Aust N Z J Obstet Gynaecol 1987;27:1-5.
29. Hnat MD, Sibai BM, Caritis S, Hauth J, Lindheimer MD, MacPherson C, et al. Perinatal outcome in women with recurrent preeclampsia compared to women who develop preeclampsia as nulliparas. Am J Obstet Gynecol 2002;186:422-6.
30. Sibai BM, Mercer B, Sarinoglu C. Severe preeclampsia in the second trimester: recurrence risk and long-term prognosis. Am J Obstet Gynecol 1991;165:1408-12.
31. Taylor DJ. The epidemiology of hypertension during pregnancy. In Rubin P, editor. Handbook of hypertension. Vol. 10. Amsterdam: Elsevier; 1988.
32. Adams EM, Finlayson A. Familial aspects of preeclampsia and hypertension in pregnancy. Lancet 1961;ii:1357.
33. Chesley LC, Annitto JE, Cosgrove RA. The familial factor in toxemia of pregnancy. Obstet Gynaecol 1968;32:303-11.
34. Baeten JM, Bukusi EA, Lambe M. Pregnancy complications and outcomes among overweight and obese nulliparous women. Am J Public Health 2001;91:436-40.
35. Sebire NJ, Jolly M, Harris JP, Wadsworth J, Joffe M, Beard RW, et al. Maternal obesity and pregnancy outcome: a study of 287,213 pregnancies in London. Int J Obes Relat Metab Disord 2001; 25: 1175-82.
36. Pridjian G, Puschett JB. Preeclampsia. Part 2: experimental and genetic considerations. Obstet Gynecol Surv 2002;57:619-40.
37. Garner PR, D'Alton ME, Dudley DK, Huard P, Hardie M. Preeclampsia in diabetic pregnancies. Am J Obstet Gynecol 1990;163:505-8.
38. Powers RW, Rhobert WE, Majors AK, Ojimba JI, Ness RB, Crombleholme WR, et al. Plasma homocysteine concentration is increased in preeclampsia and is associated with evidence of endothelial activation. Am J Obstet Gynecol 1998; 179:1605-11.
39. Mignini LE, Latthe PM, Villar J, Kilby MD, Carroli G, Khan KS. Mapping the theories of preeclampsia: the role of homocysteine. Obstet Gynaecol 2005;105:411-25.
40. Dyerberg J, Bang HO. Pre-eclampsia and prostaglandins. Lancet 1985;i:1267.
41. World Health Organization, Department of Reproductive Health and Research. RHR proposed programme budget 2006-2007. Report No. WHO/ RHR/05.10. Geneva: WHO; 2005.
42. Rotchell YE, Cruikshank JK, Phillips Gay M, Griffiths J, Stuart A, Farrell B, et al. Barbados low dose aspirin study in pregnancy (BLASP): a randomised controlled trial for the prevention of pre-eclampsia and its complications. BJOG 1998; 105:286-92.
43. Subtil D, Goeusse P, Puech F, Lequein P, Biausque S, Breart G, et al. Aspirin (100 mg) used for prevention of pre-eclampsia in nulliparous women: the Essai Regional Aspirine Mere-Enfant study (Part 1). BJOG 2003;110:475-84.
44. Golding J. A randomised trial of low dose aspirin for primiparae in pregnancy. BJOG 1998;105: 293-9.
45. Herabutya Y, Jetsawangsri T, Sarapola N. The use of low dose aspirin to prevent pre-eclampsia. Int J Obstet Gynaecol 1996;54:177-8.
46. Hauth JC, Goldenberg RL, Parker CR, Phillips JB, Copper RL, DuBard MB, et al. Low dose aspirin therapy to prevent pre-eclampsia. Am J Obstet Gynecol 1993;168:1083-93.
47. Sibai BM, Caritis S, Thorn E, Klebanoff M, McNellis D, Rocco L, et al. Prevention of preeclampsia with low dose aspirin in healthy, nulliparous pregnant women. N Engl J Med 1993;329:1213-18.
48. Anonymous. ECPPA: randomised trial of low dose aspirin for the prevention of maternal and fetal complications in high risk pregnancies. BJOG 1996;103:39-47.
49. CLASP (Collaborative Low-dose Aspirin Study in Pregnancy) Collaborative Group. CLASP: a randomised trial of low-dose aspirin for the prevention and treatment of pre-eclampsia among 9364 pregnant women. Lancet 1994;343:619-29.
50. Italian Study of Aspirin in Pregnancy. Low dose aspirin in the prevention and treatment of interuterine growth retardation and pregnancy-induced hypertension. Lancet 1993;341:396-400.
51. Volpicelli T, D'Anto V, Faticato A, Galante L, Civitillo RM, Rappa C, et al. Trial prospettico sull'uso profilattico dell'aspirina in donne gravide ad alto rischio di preeclampsia. Gestosi '99 1999; 159-60.
52. Caritis S, Sibai B, Hauth J, Lindheimer M, Klebanoff M, Thom E, et al. Low dose aspirin to prevent pre-eclampsia in women at high risk. N Engl J Med 1998;338:701-5.
53. Byaruhanga RN, Chipato T, Rusakaniko S. A randomised controlled trial of low-dose aspirin in women at risk from pre-eclampsia. Int J Obstet Gynaecol 1998;60:135.
54. Saudan P, Brown M, Buddle M, Jones M. Does gestational hypertension become pre-eclampsia? BJOG 1998;105:1177-84.
55. Thangaratinam S, Ismail K, Sharp S, Coomarasamy A, Khan K. Accuracy of serum uric acid in predicting complications of pre-eclampsia: a systematic review. BJOG 2006;113:369-78.
56. American College of Obstetricians and Gynecologists. Hypertension in pregnancy. ACOG Tech Bull 1996;219:1-8.
57. Department of Health, Scottish Executive Health Department, Department of Health, Social Services, Public Safety, Northern Ireland. Why mothers die. The sixth report on confidential enquiries into maternal deaths in the United Kingdom 2000-2002. London: RCOG Press; 2004.
58. Hannaford P, Ferry S, Hirsch S. Cardiovascular sequelae of toxaemia of pregnancy. Heart 1997;77: 154-8.
59. Wilson BJ, Watson S, Prescott GJ, Sunderland S, Campbell DM, Hannaford P, et al. Hypertensive diseases of pregnancy and risk of hypertension and stroke in later life: results from a cohort study. BMJ 2003;326:845.
60. Kramer MS, Seguin L, Lydon J, Goulet L. Socio-economic disparities in pregnancy Outcome: why do the poor fare so poorly? Paediatr Perinat Epidemiol 2000;14:194-210.
61. Hewitt BG, Newnham JP. A review of the obstetric and medical complications leading to the delivery of infants of very low birthweight. Med J Aust 1988; 149:234.
62. Khan KS, Wojdyla D, Say L, Gulmezoglu AM, Van Look PF. WHO analysis of causes of maternal death: a systematic review. Lancet 2006; 367: 1066-74.
63. Department of Health, Welsh office, Scottish Office Home and Health Department, Department of Health and Social Services, Northern, I. Why mothers die? Report on confidential enquiries into maternal deaths in the United Kingdom 1994-1996. London: The Stationery Office; 1998.
64. Ananth CV, Savitz DA, Bowes WA. Hypertensive disorders of pregnancy and stillbirth in North Carolina, 1988-1991. Acta Obstet Gynecol Scand 1995;74:788-93.
65. Rosenberg K, Twaddle S. Screening and surveillance of pregnancy hypertension - an economic approach to the use of daycare. Baillieres Clin Obstet Gynaecol 1990;4:89-107.
66. Anthony J. Improving antenatal care: the role of an antenatal assessment unit. Health Trends 1992; 24:123-5.
67. Bouvier-Colle MH, Salanave B, Ancel PY, Varnoux N, Fernandez E, Papiernik E, et al. Obstetric patients treated in intensive care units and maternal mortality. Regional teams for the survey. Eur J Obstet Gynecol Reprod Biol 1996;65: 121-5.
68. Clement S. Psychological perspectives on pregnancy and childbirth. Edinburgh: Churchill Livingstone; 1998.
69. National Collaborating Centre for Women's and Children's Health. Antenatal care. Routine care for the health pregnant woman. London: National Institute for Clinical Excellence; 2003.
70. Duley L, Meher S, Abalos E. Management of preeclampsia. BMJ 2006;332:463-8.
71. Atallah AN, Hofmeyr GJ, Duley L. Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems (Cochrane Review). The Cochrane Library 2004;(2).
72. Mahomed K. Zinc supplementation in pregnancy (Cochrane Review).
73. Makrides M, Crowther CA. Magnesium supplementation in pregnancy (Cochrane Review).
74. Duley L, Henderson-Smart DJ, Knight M, King JF. Antiplatelet agents for preventing pre-eclampsia and its complications (Cochrane Review).
75. Walker MC, Ferguson SE, Allen VM. Heparin for pregnant women with acquired or inherited thrombophilias (Cochrane Review). The Cochrane Library 2004;(2).
76. Abalos E, Duley L, Steyn DW, Henderson-Smart DJ. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy (Cochrane Review).
77. Meyer S, Duley L. Nitric oxide donors and precursors for preventing pre-eclampsia and its complications. The Cochrane Library 2005.
78. Duckett K, Harrington D. Risk factors for pre-eclampsia at ante-natal booking: systematic review of controlled studies. BMJ 2005; 330(7491):565-72.
79. Meyer S, Duley L. Interventions for preventing pre-eclampsia and its consequences: generic protocol. The Cochrane Library 2005;(2).
80. National Heart, Lung and Blood Institute. National High Blood Pressure Working Group on High Blood Pressure in Pregnancy, USA. Washington, DC: National Institutes of Health; 2000.
81. Lijmer JG, Mol BW, Heisterkamp S, Bonsel GJ, Prins MH, van der Meulen JH, et al. Empirical evidence of design related bias in studies of diagnostic tests. JAMA 1999;282:1061-6.
82. Whiting P, Rutges AW, Rietsma JB, Bossuyt PM, Kleijnen J. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol 2003;3:25.
83. Milunsky A, Jick SS, Bruell CL, MacLaughlin DS, Tsung YK, Jick H, et al. Predictive values, relative risks, and overall benefits of high and low maternal serum alpha-fetoprotein screening in singleton pregnancies: new epidemiologic data. Am J Obstet Gynecol 1989; 161:291-7.
84. Waller DK, Lustig LS, Cunningham GC, Feuchtbaum LB, Hook EB. The association between maternal serum alpha-fetoprotein and preterm birth, small for gestational age infants, preeclampsia, and placental complications. Obstet Gynecol 1996;88:816-22.
85. Yaron Y, Cherry M, Kramer RL, O'Brien JE, Hallak M, Johnson MP, et al. Second-trimester maternal serum marker screening: maternal serum alpha-fetoprotein, beta-human chorionic gonadotropin, estriol, and their various combinations as predictors of pregnancy outcome. Am J Obstet Gynecol 1999;181:968-74.
86. Newcombe R.G. Two-sided confidence intervals for the single proportion: comparison of seven methods. Stat Med 1998;17:857-72.
87. Van Houwelingen HC, Zwinderman KH, Stijnen T. A bivariate approach to meta-analysis. Stat Med 1993;12:2273-84.
88. Van Houwelingen HC, Arends LR, Stijnen T. A bivariate approach to meta-analysis. Stat Med 2002;21:589-624.
89. Cochrane Reviewers' Handbook 4.2.0 [updated March 2003]. In Clarke M, Oxman AD, editors. The Cochrane Library, Issue 2. Oxford: Update Software; 2003.
90. Conde-Agudelo A, Villar J, Lindheimer M. World Health Organization systematic review of screening tests for preeclampsia. Obstet Gynaecol 2004;104:1367-91.
91. Rutjes AW, Reitsma JB, Di Nisio M, Smidt N, van Rijn JC, Bossuyt PM. Evidence of bias and variation in diagnostic accuracy studies. CMAJ 2006;174:469-76.
92. Ransohoff DF, Feinstein AR. Problems of spectrum and bias in evaluating the efficacy of diagnostic tests. N Engl J Med 1978; 299:926-30.
93. Lachs MS, Nachamkin I, Edelstein PH, Goldman J, Feinstein AR, Schwartz JS. Spectrum bias in the evaluation of diagnostic tests: lessons from the rapid dipstick test for urinary tract infection. Ann Intern Med 1992;117:135-40.
94. Bachmann LM, ter Riet G, Weber W, Kessels A. Multivariable adjustments counteract spectrum bias and test review bias in test accuracy studies. J Clin Epidemiol, accepted for publication.
95. Leeflang M, ReitsmaJ, Scholten R, Rutjes A, DiNisio M, Deeks J, et al. Impact of adjustment for quality on results of metaanalyses of diagnostic accuracy. Clin Chem 2007;53:1-9.
96. Siadaty MS, Philbrick JT, Heim SW, Schectman JM. Repeated-measures modeling improved comparison of diagnostic tests in meta-analysis of dependent studies. J Clin Epidemiol 2004;57: 698-711.
97. Bergel E, Carroli G, Althabe FB, Carroli G, Althabe FCL. Ambulatory versus conventional methods for monitoring blood pressure during pregnancy (Cochrane Review). The Cochrane Library 2004;(2).
98. Meher S, Abalos E, Carroli G. Bed rest with or without hospitalisation for hypertension during pregnancy. Cochrane Database Syst Rev 2005;4.
99. Crowther CA, Bouwmeester AM, Ashurst HM. Does admission to hospital for bed rest prevent disease progression or improve fetal outcome in pregnancy complicated by non-proteinuric hypertension? BJOG 1992;99:13-17.
100. Leung KY, Sum TK, Tse CY, Law KM, Chan MY. Is in-patient management of diastolic blood pressure between 90 and 100 mmHg during pregnancy necessary? Hong Kong Med J 1998;4:217.
101. Crowther CA. Strict bed rest vs ambulation in the management of patients with proteinuric hypertension in pregnancy. 1986; unpublished.
102. Mathews DD, Agarwal V, Shuttleworth TP. A randomised controlled trial of complete bed rest vs ambulation on plasma urea and urate levels in pregnant women with proteinuric hypertension. BJOG 1980; 87:1095-8.
103. Meher S, Duley L. Exercise or other physical activity for preventing pre-eclampsia and its complications (Cochrane Review). The Cochrane Library 2006(2).
104. Avery MD, Leon AS, Kopher RA. Effects for a partially home-based exercise program for women with gestational diabetes. Obstet Gynaecol 1997;89: 10-15.
105. Yet S, Steele N, Chang M-C, Leclaire S, Rovis D, Hayashi R. Effect of exercise on blood pressure in pregnant women with a high risk of gestational hypertensive disorders. J Reprod Med 2000;45: 293-8.
106. Meher S, Duley L. Rest for preventing preeclampsia and its complications in women with normal blood pressure (Cochrane [Review). The Cochrane Library 2006(2).
107. Spinapolice RX, Feld S, Harrigan JT. Effective prevention of gestational hypertension in nulliparous women at high risk as identified by the rollover test. Am J Obstet Gynecol 1983;146:166-8.
108. Herrera JA. Nutritional factors and rest reduce pregnancy induced hypertension and preeclampsia in positive roll-over test primagravidas. Int J Gynecol Obstet 1993;41:31-5.
109. Duley L, Henderson-Smart, D. Reduced salt intake compared to normal dietary salt, or high intake, in pregnancy (Cochrane Review).
110. van Buul E, Rijpkema A, Steegers E, Jonggsma T, Eskes P. Dietary sodium restriction does not prevent gestational hypertension: a Dutch two-centre randomised trial. Hypertens Pregnancy 1997; 16:335-46.
111. Knuist M, Bonsel GJ, Zondervan HA, Treffers PE. Low sodium diet and pregnancy-induced hypertension: a multi-centre randomised controlled trial. BJOG 1998;105:430-4.
112. Rumbold A, Duley L, Crowther C, Haslam R. Antioxidants for preventing pre-eclampsia. Cochrane Database Syst Rev 2005;4.
113. Beazley D, Livingston J, Kao L, Sibai B. Vitamin C and E supplementation in women! at high risk for preeclampsia: a double-blind placebo controlled trial [abstract]. Am J Obstet Gynecol 2002; 187 (6 Pt 2):S216.
114. Sharma JB, Kumar A, Kumar A, Malhotra M, Arora R, Prasad S, et al. Effect of lycopene on preeclampsia and intra-uterine growth retardation in primigravidas. Int J Gynecol Obstet 2003;81:257-62.
115. Han L, Zhou SM. Selenium supplement in the prevention of pregnancy induced hypertension. Chin Med J 1994;107:870-1.
116. Chappell L, Seed P, Briley A, Kelly F, Lee R, Hunt BB. Effect of antioxidants on the occurrence of pre-eclampsia in women at increased risk: a randomised controlled trial. Lancet 1999;354: 810-16.
117. Steyn P, Odendaal H, Schoeman J, Grove D. Vitamin C, pre-eclampsia and preterm labour: a randomized, placebo-controlled, double blind trial [abstract]. Hypertens Pregnancy 2002; 21(Suppl 1):43.
118. People's League of Health. The nutrition of expectant and nursing mothers in relation to maternal and infant mortality and morbidity. J Obstet Gynaecol Br Emp 1946;53:498-509.
119. Rivas-Echeverria CA, Echeverria Y, Molina L, Novoa D. Synergic use of aspirin, fish oil and vitamins C and E for the prevention of preeclampsia [abstract]. Hypertens Pregnancy 2000; 19(Suppl 1):30.
120. Levine RJ, Hauth JC, Curer LB, Sibai BM, Catalano PM, Morris CD, et al. Trial of calcium to prevent preeclampsia. N Engl J Med 1997;337: 69-76.
121. Villar J, Abdel-Aleem H, Merialdi M, Mathai M, Ali M, Zavaleta N, et al. World Health Organization randomised trial of calcium supplementation among low calcium intake pregnant women. Am J Obstet Gynecol 2006;194: 639-49.
122. Belizan JM, Villar J, Gonzalez L, Campodonico L, Bergel E. Calcium supplementation to prevent hypertensive disorders of pregnancy. N Engl J Med 1991;325:1399-405.
123. Levine RJ, Hauth JC, Curet LB, Sibai BM, Catalano PM, Morris CD, et al. Trial of calcium to prevent preeclampsia. N Engl J Med 1997;337: 69-76.
124. Crowther CA, Hiller JE, Pridmore B, Bryce R, Duggan P, Hague WM, et al. Calcium supplementation in nulliparous women for the prevention of pregnancy-induced hypertension, preeclampsia and preterm birth: an Australian randomized trial. Aust N Z J Obstet Gynaecol 1999; 39:12-18.
125. Lopez JP, Delgado F, Jacome P, Teran E, Ruano C, Rivera J. Calcium supplementation and the risk of preeclampsia in Ecuadorian pregnant teenagers. Obstet Gynecol 1997;90:162-7.
126. Sanchez RL, Briones DK, Kaunitz AM, Delvalle GO, Gaudier FL, Walker KD. Prevention of pregnancy-induced hypertension by calcium supplementation in angiotensin II-sensitive patients. Obstet Gynecol 1994; 84:349-53.
127. Villar J, Repke J, Belizan JM, Pareja G. Calcium supplementation reduces blood pressure during pregnancy: results of a randomized controlled clinical trial. Obstet Gynecol 1987;70:317-22.
128. Villar J, Repke JT. Calcium supplementation during pregnancy may reduce preterm delivery in high-risk populations. Am J Obstet Gynecol 1990; 163:1124-31.
129. Lopez JP, Narvaez M, Weigel RM, Yepez R. Calcium supplementation reduces the risk of pregnancy-induced hypertension in an Andes population. BJOG 1989;96:648-55.
130. Lopez JP, Narvaez M, Felix C, Lopez A. Dietary calcium supplementation and prevention of pregnancy hypertension. Lancet 1990; 335:293.
131. Niromanesh S, Laghaii S, Mosavi JA. Supplementary calcium in prevention of preeclampsia. Int J Gynecol Obstet 2001;74:17-21.
132. Purwar M, Kulkarni H, Motghare V, Dhole S. Calcium supplementation and prevention of pregnancy induced hypertension. J Obstet Gynaecol Res 1996;22:425-30.
133. Kramer MS, Kakuma R. Energy and protein intake in pregnancy (Cochrane Review).
134. Blackwell RQ, Chow BF, Chinn KS, Blackwell BN, Hsu SC. Prospective maternal nutrition study in Taiwan: rationale, study design, feasability and preliminary findings. Nut Rep Int 1973;7:517-32.
135. Iyengar L. Effects of dietary supplements late in pregnancy on the expectant mother and her newborn. Indian J Med Res 1967; 55:85-9.
136. Kardjati S, Kusin JA, De With C. Energy supplementation in the last trimester of pregnancy in East Java. BJOG 1988;95:783-94.
137. Mardones-Santander F, Rosso P, Stekel A, Ahumada E, Llaguno S, Pizzaro F, et al. Effect of a milk-based food supplement on maternal nutritional status and foetal growth in underweight Chilean women. Am J Clin Nutr 1988;47:413-19.
138. Ross SM, Nel E, Naeye RL. Differing effects of low and high bulk maternal dietary supplements during pregnancy. Early Hum Dev 1985;10: 295-302.
139. Rush D, Stein Z, Susser M. A randomised controlled trial of prenatal nutritional supplementation in New York City. Pediatrics 1980; 65:683-97.
140. Viegas OA, Scott PH, Cole TJ, Mansfield HN, Wharton P, Wharton BA. Dietary protein energy supplementation of pregnant Asian mothers at Sorrento, Birmingham. I. Unselective during second and third trimesters. BMJ 1982;285: 589-92.
141. Viegas OA, Scott PH, Cole TJ, Eaton P, Needham PG, Wharton BA. Dietary protein energy supplementation of pregnant Asian mothers at Sorrento, Birmingham. II. Selective during third trimester only. BMJ 1982; 285:592-5.
142. Atton C, Watney PJ. Selective supplementation in pregnancy: effect on birth weight. J Hum Nutrit Dietet 1990;3:381-92.
143. Campbell Brown M. Protein energy supplements in primigravid women at risk of low birthweight. In Campbell DM, Gillmer MD, editors. Nutrition in pregnancy. Proceedings of the 10th study group of the RCOG. London: RCOG; 1983. pp. 85-98.
144. Girija A, Geervani P, Rao GN. Influence of dietary supplementation during pregnancy on lactation performance. J Trop Paediatr 1984; 30:79-83.
145. Hankin ME, Symonds EM. Body weight, diet and pre-eclamptic toxaemia of pregnancy. Aust N Z J Obstet Gynaecol 1962;4:156-60.
146. Ross SM, Perlzweig WA, Taylor HM, McBryde A, Yates A, Kondritzer AA, et al. A study of certain dietary factors of possible aetiological significance in toxaemias of pregnancy. Am J Obstet Gynaecol 1938;35:426-40.
147. Meher S, Duley L. Garlic for preventing preeclampsia and its complications (Cochrane Review). The Cochrane Library 2006(3).
148. Zaiei S, Hantoshzadeh S, Rezasoltani P, Lamyian M. The effect of garlic tablets on plasma lipids and platelet aggregation in nulliparous pregnants at high risk of pre-eclampsia. Eur J Obstet Gynecol Reprod Biol 2001;99:201-6.
149. D'Almeida A, Carter JP, Anatol A, Prost C. Effects of a combination of evening primrose oil (gamma linolenic acid) and fish oil (eicosapentaenoic + docosahexaenoic acid) versus magnesium, and versus placebo in preventing pre-eclampsia. Women Health 1992; 19:117-31.
150. Arikan G, Gucer F, Scholl W, Weiss PA. [Preterm labour during oral magnesium supplementation in uncomplicated pregnancies]. Geburtshilfe und Frauenheilkunde 1997;57:491-5.
151. Li S, Tian H. [Oral low-dose magnesium gluconate preventing pregnancy induced hypertension]. Chin J Obstet Gynaecol 1997; 32:613-15.
152. Martin RW, Perry KG, Hess LW, Martin JN, Morrison JC. Oral magnesium and the prevention of pre-term labour in a high-risk group of patients. Am J Obstet Gynecol 1992;166:144-7.
153. Kovacs L, Molnar BG, Huhn E, Bodis L. Magnesiumsubstitution in der Schwangerschaft: eine prospektive, randomisierte doppelblindstudie. Geburtshilfe und Frauenheilkunde 1988;48:595-600.
154. Sibai BM, Villar J, Bary E. Magnesium supplementation during pregnancy: a double blind randomised controlled clinical trial. Am J Obstet Gynecol 1989;161:115-19.
155. Spatling L, Spatling G. Magnesium supplementation in pregnancy, a double blind study. BJOG 1988;95:120-5.
156. Makrides M, Duley L, Olsen SF. Marine oil and other prostaglandin precursor supplementation during pregnancy for reducing pre-eclampsia, preterm birth, low birth weight and intrauterine growth restriction (Cochrane Review). The Cochrane Library 2006(3).
157. Olsen SF, Dalby SJ, Secher NJ, Hedegaard M, Brink HT, Hansen HS, et al. Randomised controlled trial of effect of fish-oil supplementation on pregnancy duration. Lancet 1992;339:1003-7.
158. Olsen SF, Secher NJ, Tabor A, Weber T, Walker JJ, Gluud C. Randomised clinical trials of fish oil supplementation in high risk pregnancies. BJOG 2000;107:382-95.
159. Onwude JL, Lilford RJ, Hjartardottir H, Staines A, Tuffnell D. A randomised double blind placebo controlled trial of fish oil in high risk pregnancy. BJOG 1995;102:95-100.
160. Bulstra-Ramakers MTEW, Huisjes Hj, Visser GHA. The effects of 3 g eicosapentaenoic acid daily on recurrence of intrauterine growth retardation and pregnancy induced hypertension. BJOG 1994; 102:123-6.
161. Smuts CM, Huang M, Mundy D, Plasse T, Major S, Carlson SE. A randomized trial of docosahexaenoic acid supplementation during the third trimester of pregnancy. Obstet Gynecol 2003;101:469-79.
162. Plouin PF, Breart G, Llado J, Dalle M, Keller ME, Goujon HH. A randomized comparison of early with conservative use of antihypertensive drugs in the management of pregnancy-induced hypertension. BJOG 1990;97:134-41.
163. Bott KG, Hirsch M, Friedman S, Boner G, Ovadia J, Merlob PP. Antihypertensiye therapy in the management of hypertension in pregnancy - a clinical double-blind study of pindolol. Clin Exp Hypertens 1992;B11:207-20.
164. Gruppo di Studio Ipertensione in Gravidanza. Nifedipine versus expectant management in mild to moderate hypertension in pregnancy. BJOG 1998;105:718-22.
165. Pickles CJ, Broughton PF, Symonds EM. A randomised placebo controlled trial of labetalol in the treatment of mild to moderate pregnancy induced hypertension. BJOG 1992;99:964-8.
166. Cruickshank DJ, Robertson AA, Campbell DM, MacGillivray I. Maternal obstetric outcome measures in a randomised controlled study of labetalol in the treatment of hypertension in pregnancy. Clin Exp Hyperten 1991;B10:333-4.
167. Uzan M, Beaufils M, Breart G, Bazin B, Capitant C, Paris J. Prevention of foetal growth retardation with low-dose aspirin: findings of the EPREDA trial. Lancet 1991;337:1427-31.
168. Beaufils M, Uzan S, Donisimoni R, Colau JC. Prevention of pre-eclampsia by early platelet therapy. Lancet 1985;i:840-2.
169. Azar R, Turpin D. Effect of anti-platelet therapy in women at high risk for pregnancy-induced hypertension. In Proceedings of the 7th World Congress of Hypertension in Pregnancy: Perugia, Italy 1990. p. 257.
170. Railton A, Davey A. Aspirin and dipyridamole in the prevention of pre-eclampsia: effect on plasma 6 keto PGF1alpha and TxB2 and clinical outcome of pregnancy. In Proceedings of the 1st European Conference on Prostoglandins in Reproduction: Vienna, Austria 1988. p. 48.
171. Rivas-Echeverria CA, Echeverria Y, Molina L, Novoa D. Synergic use of aspirin, fish oil and vitamins C and E for the prevention of preeclampsia. Hypertens Pregnancy 2000;19:30.
172. Kincaid-Smith P, North RA, Fairley KF, Kloss M, Uhle BU. Prevention of pre-eclampsia in high risk women with renal disease: a prospective randomised trial of heparin and dipyridamole. Nephrology 1995; 1:297-300.
173. Seki H, Kuromaki K, Takeda S, Kinoshita K, Satoh K. Trial of prophylactic administration of TXA2 synthetase inhibitor, ozagrel hydrochloride, for pre-eclampsia. Hypertens Pregnancy 1999;
174. Churchill D, Beevers G, Meher S, Rhodes C. Diuretics for preventing pre-eclampsia (Cochrane Review). The Cochrane Library 2007(1).
175. Fallis NE, Plauche WC, Mosey LM, Langford HG. Thiazide vs placebo in prophylaxis of toxemia of pregnancy in primigravid patients. Am J Obstet Gynecol 1964;88:502-4.
176. Weseley AC, Douglas GW. Continuous use of chlorothiazide for prevention of toxemia of pregnancy. Obstet Gynecol 1962;19:355-8.
177. Sibai BM, Grossman RA, Grossman HG. Effects of diuretics on plasma volume in pregnancies with long-term hypertension. Am J Obstet Gynecol 1984; 150:831-5.
178. Flowers CE, Grizzle JE, Easterling WE, Bonner OB. Chlorthiazide as a prophylaxis against toxemia of pregnancy. Am J Obstet Gynecol 1962;84:919-29.
179. Kraus GW, Marchese JR, Yen SSC. Prophylactic use of hydrochlorothiazide in pregnancy. JAMA 1966; 198:128-32.
180. Meher S, Duley L. Nitric oxide donors and precursors for pre-eventing pre-eclampsia and its complications (Cochrane Review). The Cochrane Library 2007(2).
181. Neri I, Valensise H, Fachinetti F, Menghini S, Romanini C, Volpe A. 24-hour ambulatory blood pressure monitoring: a comparison between transdermal glyceryl-trinitrate and oral nifedipine. Hypertens Pregnancy 1999;18:107-13.
182. Zozulia O, Rogov VA, Piatakova NV, Tareeva IE. Nitric oxide: its role in the development of pregnancy complications and in their prevention in women with hypertension and chronic glomerulonephritis. Ter Arkh 1997;69(6):17-20.
183. Davis G, Brown M. Glyceryl trinitrate patches are unsuitable in hypertensive pregnancy. Aust J Obstet Gynaecol 2001;41:474.
184. Facchinetti F, Piccinini F, Pizzi C, Bukowski R, Volpe A, Saade G. Effect of arginine supplementation in patients with gestational hypertension (abstract). Am J Obstet Gynecol 2002;187(6 Pt 2):S213.
185. Picciolo C, Roncaglia N, Neri I, Pasta F, Arreghini A, Facchinetti F. Nitric oxide in the prevention of pre-eclampsia. Prenat Neonat Med 2000;5:212-15.
186. Lees C, Valensise H, Black R, Harrington K, Byiers S, Romanini C, et al. The efficacy and fetal-maternal cardiovascular effects of transdermal glyceryl trinitrate in the prophylaxis of preeclampsia and its complications: a randomized double-blind placebo-controlled trial. Ultrasound Obstet Gynecol 1998;12:334-8.
187. Meher S, Duley L. Progesterone for preventing pre-eclampsia and its complications (Cochrane Review). The Cochrane Library 2006(4).
188. Dalton K. Controlled trials in the prophylactic value of progesterone in the treatment of preeclamptic toxaemia. J Obstet Gynaecol Br Commonw 1969;3:463-8.
189. Magee LA, Duley L. Oral beta-blockers for mild to moderate hypertension during pregnancy (Cochrane Review).
190. De Bono M, Fawdry RD, Lilford RJ. Size of trials for evaluation of antenatal tests of fetal wellbeing in high-risk pregnancy. J Perinat Med 1990;18: 77-87.
191. Roberts T, Henderson J, Mugford M, Bricker L, Neilson J, Garcia J. Antenatal ultrasound screening for fetal abnormalities: a systematic review of cost and cost effectiveness studies. BJOG 2002; 109(1):44-56.
192. Petrou S, Henderson J, Roberts T, Martin MA. Recent economic evaluations of antenatal screening: a systematic review and critique. J Med Screen 2000;7:59-73.
193. Curtis L, Netten A. Unit costs of health and social care 2005. Canterbury: PSSRU; 2006.
194. International Monetary Fund. Exchange rate archives by month. URL: http://www.imf.org/external/np/fin/rates/param_mss_mth.cfm. Accessed May 2006.
195. Low N, McCarthy A, Macleod J, Salisbury C, Campbell R, Roberts T, et al. Epidemiological, social, diagnostic and economic evaluation of population screening for genital chlamydial infection. Health Technol Assess 2007;11(8).
196. British Medical Association and Royal Pharmaceutical Society of Great Britain. British National Formulary. 2006.
197. Holland and Barrett. URL: http://www.hollandandbarrett.com/
198. Simon J, Gray A, Duley L, Magpie Trial Collaborative Group. Cost-effectiveness of prophylactic magnesium sulphate for 9996 women with pre-eclampsia from 33 countries: economic evaluation of the Magpie Trial. BJOG 2006;113: 144-51.
199. Department of Health. Reference costs 2005. London: Department of Health; 2005.
200. Coomarasamy A, Braunholtz D, Song F, Taylor R, Khan KS. Individualising use of aspirin to prevent pre-eclampsia: a framework for clinical decision making. BJOG 2003;110:882-8.
201. Davey DA, MacGillivray I. The classification and definition of the hypertensive disorders of pregnancy. Am J Obst Gynaecol 1988: 158: 892-8.